Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Next Previous
Trial Profile

A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cendakimab (Primary) ; Cendakimab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HEROES
  • Sponsors Celgene Corporation; Receptos

Most Recent Events

  • 09 May 2024 According to an Intercept Pharmaceuticals media release, data from this study will be presented at the Digestive Disease Week (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C.
  • 17 Oct 2023 Results presented at the 31st United European Gastroenterology Week
  • 01 Apr 2023 Results of post hoc analysis assessing the dysphagia days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study, published in the American Journal of Gastroenterology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top